NKGen Biotech partners with HekaBio to develop troculeucel in Japan

NKGen Biotech, Inc.

HekaBio leads Japan clinical trials and regulatory activities; first dosing targeted within 12 months.
Profit sharing: HekaBio gets 70% of net profits until cost recovery, then 45% HekaBio / 55% NKGen.
Partnership follows HekaBio's strategic equity investment in NKGen (amount undisclosed).
NKGen retains buy-out option at 6.5x unrecovered costs or most recent 12-month net profits.
15-year initial term with auto-renewal; NKGen supplies product at no cost for clinical trials.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.